Jpmorgan Chase & CO Nuvectis Pharma, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Nuvectis Pharma, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 14,753 shares of NVCT stock, worth $107,696. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,753
Previous 5,165
185.63%
Holding current value
$107,696
Previous $42,000
121.43%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding NVCT
# of Institutions
40Shares Held
1.83MCall Options Held
0Put Options Held
0-
Ronit Capital LLP563KShares$4.11 Million5.37% of portfolio
-
Vanguard Group Inc Valley Forge, PA251KShares$1.83 Million0.0% of portfolio
-
Baldwin Brothers LLC174KShares$1.27 Million0.08% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny119KShares$872,0500.0% of portfolio
-
Black Rock Inc. New York, NY83.4KShares$608,9070.0% of portfolio
About Nuvectis Pharma, Inc.
- Ticker NVCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 14,642,500
- Market Cap $107M
- Description
- Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src...